FDA Seeks Regulatory Flexibility - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Seeks Regulatory Flexibility
Quality-by-design submissions may reduce supplements and improve change management.


Pharmaceutical Technology
Volume 3, Issue 32


Jill Wechsler
The US Food and Drug Administration has been encouraging manufacturers to expand applications to include discussions of how process knowledge and a full understanding of critical product parameters ensure drug quality. Adopting quality-by-design (QbD) approaches offers manufacturers important benefits and savings, as well as the potential for regulatory relief. FDA may waive the requirement to file supplements that describe postapproval manufacturing changes. The agency is also considering further reductions to the scope and frequency of plant inspections for companies that demonstrate risk management and modern manufacturing approaches.

Although such initiatives are gaining more currency in industry, formally establishing regulatory relief has been more difficult. FDA officials are anxious to reduce the number of supplements manufacturers file with the agency but cannot decide exactly how. A proposal that manufacturers could negotiate a "regulatory agreement" with the Center for Drug Evaluation and Research (CDER) fell by the wayside because it seemed too much like a legal agreement that would oblige the agency to take certain actions.

Extending CMC pilot

Initiatives to provide regulatory flexibility are moving forward now because of wider industry adoption of QbD approaches. The Office of New Drug Quality Assessment (ONDQA) in CDER's Office of Pharmaceutical Science (OPS) initiated a chemistry, manufacturing, and controls (CMC) pilot program to assess the value of applications that contain more scientific information about product development and formulation than typical new drug applications do. ONDQA has reviewed and approved six pilot applications that demonstrate an understanding of critical quality attributes, process development, and design space. Several more applications await assessment.

The success of this program for drugs is encouraging regulators to extend it to biotechnology therapies. OPS's Office of Biotechnology Products (OBP) is inviting biotechnology manufacturers to submit QbD information, demonstrate process control, and define products' critical attributes. At the January WCBP conference on biotechnology regulation and analysis, in Washington, OPS Director Helen Winkle explained that this information looks like an expanded comparability protocol for biologics. And because relatively few new biologics license applications are filed each year, Winkle thinks the biotech QbD pilot will primarily examine manufacturing supplements.


In Washington This Month
OBP director Steven Kozlowski recognizes that defining product attributes and design space is more complex for biotechnology products. Compared with small-molecule drugs, finished biological products often have lower heterogeneity, and later manufacturing steps are more likely to change the product, he noted at a workshop last year. The manufacturer's challenge is to determine what data are relevant in defining critical product attributes. For innovative oncology products moving quickly through development and review, it may be very difficult to include QbD data in an initial market application.

FDA is encouraging manufacturers to share information about the development of product-control strategies and process analytical technology to better define what constitutes a QbD-based submission and science-based risk assessment. Many manufacturers have adopted modern manufacturing methods, but have been afraid that providing information about such innovations would raise more questions, delay application approvals, and generate objections from field inspectors.

To dispel such concerns, FDA would like to hold a workshop with industry to evaluate science-based risk assessment and lessons learned from the pilot exercise. Winkle and her colleagues regard the CMC pilot as a means to help FDA understand the difficulties in defining critical attributes. Some filings have inadequate quality information; others have too much data. Fully evaluating the drug pilot, Winkle notes, would improve the program for biotechnology therapies.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here